Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

358 ARTÍCULOS , VIENDO DEL 226 AL 240

Pharmacological treatments of behavioral and psychological symptoms of dementia in Alzheimer's disease: role of acetylcholinesterase inhibitors and memantine

Desmidt T, Hommet C, Camus V.

Geriatr Psychol Neuropsychiatr Vieil. 2016 Sep 1;14(3):300-6. doi: 10.1684/pnv.2016.0621.

Evaluating the Role of Hormone Therapy in Postmenopausal Women with Alzheimer's Disease

Osmanovic-Barilar J, Salkovic-Petrisi M.

Drugs Aging. 2016 Nov;33(11):787-808. doi: 10.1007/s40266-016-0407-9.

Multiple Targets for the Management of Alzheimer's Disease

Ahmad SS, Akhtar S, Jamal QM, Rizvi SM, Kamal MA, Khan MK, Siddiqui MH.

CNS Neurol Disord Drug Targets. 2016;15(10):1279-1289. doi: 10.2174/1871527315666161003165855.

ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension

Gault LM, Lenz RA, Ritchie CW, Meier A, Othman AA, Tang Q, Berry S, Pritchett Y, Robieson WZ.

Alzheimers Res Ther. 2016 Oct 18;8(1):44. doi: 10.1186/s13195-016-0210-1.

A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer's disease

Deardorff WJ, Grossberg GT.

Drug Des Devel Ther. 2016 Oct 3;10:3267-3279. doi: 10.2147/DDDT.S86463. eCollection 2016.

Effect of concomitant use of memantine on mortality and efficacy outcomes of galantamine-treated patients with Alzheimer's disease: post-hoc analysis of a randomized placebo-controlled study

Hager K, Baseman AS, Nye JS, Brashear HR, Han J, Sano M, Davis B, Richards HM.

Alzheimers Res Ther. 2016 Nov 15;8(1):47. doi: 10.1186/s13195-016-0214-x.

Alzheimer's disease: expedition into the unknown

The Lancet.

Lancet. 2016 Dec 3;388(10061):2713. doi: 10.1016/S0140-6736(16)32457-6. Epub 2016 Dec 2.

Special Issue: "Molecules against Alzheimer"

Decker M, Muñoz-Torrero D.

Molecules. 2016 Dec 16;21(12):1736. doi: 10.3390/molecules21121736.

Noradrenergic System in Down Syndrome and Alzheimer's Disease A Target for Therapy

Phillips C, Fahimi A, Das D, Mojabi FS, Ponnusamy R, Salehi A.

Curr Alzheimer Res. 2016;13(1):68-83. doi: 10.2174/1567205012666150921095924.

[Cognitive rehabilitation in early stage Alzheimer's disease]

Kasper E, Thöne-Otto A, Bürger K, Schröder SG, Hoffmann W, Schneider W, Teipel S.

Nervenarzt. 2016 Jul;87(7):708-18. doi: 10.1007/s00115-015-4426-2.

Alzheimer's Disease Risk and Progression: The Role of Nutritional Supplements and their Effect on Drug Therapy Outcome

Giulietti A, Vignini A, Nanetti L, Mazzanti L, Di Primio R, Salvolini E.

Curr Neuropharmacol. 2016;14(2):177-90. doi: 10.2174/1570159x13666150928155321.

Recent Updates on the Association Between Alzheimer's Disease and Vascular Dementia

Ashraf GM, Chibber S, Mohammad, Zaidi SK, Tabrez S, Ahmad A, Shakil S, Mushtaq G, Baeesa SS, Kamal MA.

Med Chem. 2016;12(3):226-37. doi: 10.2174/1573406411666151030111820.

Atorvastatin May Correct Dyslipidemia in Adult Patients at Risk for Alzheimer's Disease Through an Anti-Inflammatory Pathway

Zhao L, Zhao Q, Zhou Y, Zhao Y, Wan Q.

CNS Neurol Disord Drug Targets. 2016;15(1):80-5. doi: 10.2174/1871527315999160111160143.

Can ketones compensate for deteriorating brain glucose uptake during aging? Implications for the risk and treatment of Alzheimer's disease

Cunnane SC, Courchesne-Loyer A, St-Pierre V, Vandenberghe C, Pierotti T, Fortier M, Croteau E, Castellano CA.

Ann N Y Acad Sci. 2016 Mar;1367(1):12-20. doi: 10.1111/nyas.12999. Epub 2016 Jan 14.

Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer's Disease With Aggression or Agitation: The CitAD Randomized Clinical Trial

Schneider LS, Frangakis C, Drye LT, Devanand DP, Marano CM, Mintzer J, Mulsant BH, Munro CA, Newell JA, Pawluczyk S, Pelton G, Pollock BG, Porsteinsson AP, Rabins PV, Rein L, Rosenberg PB, Shade D, Weintraub D, Yesavage J, Lyketsos CG; CitAD Research Group.

Am J Psychiatry. 2016 May 1;173(5):465-72. doi: 10.1176/appi.ajp.2015.15050648. Epub 2016 Jan 15.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias